Fact-checked by Grok 2 weeks ago

Aminoacyl tRNA synthetase

Aminoacyl-tRNA synthetases (aaRSs) are a family of enzymes that catalyze the attachment of specific to their cognate (tRNA) molecules, ensuring the accurate of genetic information into proteins during protein . These enzymes are universally conserved across all domains of life and represent an ancient innovation from the (LUCA), underscoring their fundamental role in cellular . In most organisms, there are 20 standard aaRSs, each dedicated to one of the 20 proteinogenic , with additional specialized synthetases for non-standard amino acids like (SepRS) and pyrrolysine (PylRS), bringing the total to 23 in some . Eukaryotes possess distinct cytosolic and mitochondrial isoforms, allowing compartmentalized protein tailored to cellular needs. Structurally, aaRSs are classified into two distinct classes based on their catalytic domain architecture. Class I synthetases, which include those for amino acids like , , and , feature a Rossmann nucleotide-binding fold with conserved HIGH and KMSKS motifs essential for ATP binding and . In contrast, Class II synthetases, such as those for serine, , and , are characterized by antiparallel β-sheets flanked by α-helices and three conserved motifs that facilitate substrate recognition. Each class is further subdivided into three subgroups (Ia–Ic and IIa–IIc), reflecting evolutionary divergences and functional specializations. Many aaRSs also contain anticodon-binding domains for tRNA specificity and editing domains to hydrolyze misacylated products, preventing translational errors through a "double-sieve" mechanism. The catalytic function of aaRSs proceeds in two steps: first, the amino acid is activated by ATP to form an aminoacyl-adenylate intermediate, releasing pyrophosphate; second, this activated amino acid is transferred to the 3'-end of the cognate tRNA, forming aminoacyl-tRNA and releasing AMP. This aminoacylation reaction is highly specific, with fidelity enhanced by proofreading in about half of the aaRSs (pre-transfer and post-transfer editing), which is critical for maintaining the genetic code's accuracy and avoiding proteotoxic stress. Beyond their core role in translation, aaRSs participate in non-canonical functions, including transcriptional regulation, RNA splicing, angiogenesis, immune signaling (e.g., via cytokine-like fragments), and interactions with pathways like mTORC1. In eukaryotes, several aaRSs assemble into a multisynthetase complex (MSC) containing up to nine enzymes, which not only optimizes tRNA charging but also facilitates these extratranslational activities. Dysfunction in aaRSs is implicated in various human diseases, highlighting their broader physiological importance. Mutations in genes encoding aaRSs are linked to neuropathies like Charcot-Marie-Tooth disease, as well as cancers, autoimmune disorders, and neurodegenerative conditions, often due to impaired translation or aberrant signaling. Their evolutionary conservation and multifaceted roles make aaRSs promising targets for therapeutic interventions, including antibiotic development against bacterial pathogens and small-molecule modulators for disease treatment.

Overview and Biological Role

Definition and General Function

Aminoacyl-tRNA synthetases (aaRSs) are a family of enzymes that catalyze the attachment of specific to the 3' terminus of their corresponding transfer RNAs (tRNAs), forming that serve as substrates for protein synthesis on the . This esterification process links the to the of proteins by ensuring that each is paired with the tRNA bearing the anticodon that recognizes its corresponding codon in (mRNA). The general function of aaRSs is to maintain the fidelity of by selectively charging each of the 20 standard with its tRNA, a process that requires and occurs in all living cells. While most are served by a single aaRS, some, such as and serine, have dedicated synthetases for cytoplasmic and mitochondrial , reflecting adaptations to compartmentalized protein synthesis. This specificity ensures accurate codon-anticodon matching during ribosomal decoding, preventing errors that could disrupt protein function. The overall aminoacylation reaction can be summarized as: \text{Amino acid} + \text{tRNA} + \text{ATP} \rightarrow \text{aminoacyl-tRNA} + \text{AMP} + \text{PP}_\text{i} In this reaction, the carboxyl group of the amino acid forms a high-energy ester bond with the 3'-hydroxyl group of the terminal adenosine residue on the tRNA, providing the energy needed for peptide bond formation during translation. aaRSs were first identified in the 1950s by Mahlon Hoagland, Paul Zamecnik, and Mary Stephenson through studies of cell-free protein synthesis systems, where they observed ATP-dependent activation of amino acids prior to incorporation into polypeptides. These enzymes are universally conserved across all domains of life—bacteria, archaea, and eukaryotes—underscoring their ancient origin and essential role in the central dogma of molecular biology. In humans, 37 genes encode aaRSs, including isoforms for cytoplasmic and mitochondrial compartments to support proteome synthesis in both environments.

Specificity in Translation

Aminoacyl-tRNA synthetases (aaRSs) ensure high fidelity in protein by precisely recognizing and pairing the correct with its tRNA among the 20 standard and multiple isoacceptor tRNAs. This specificity is achieved through specialized -binding pockets that exploit differences in size, shape, charge, and hydrophobicity, often aided by metal ions like in enzymes such as threonyl-tRNA synthetase, which discriminates from . Similarly, anticodon-binding sites on aaRSs interact with specific in the tRNA anticodon loop and other identity elements, such as the discriminator base at position 73 or the G3-U70 pair in tRNA, enabling multi-domain coordination to verify tRNA identity without mischarging non-cognate substrates. Initial selection mechanisms provide discrimination against non-cognate of about 100- to 200-fold (error rate ~1/100 to 1/200), with further enhancing accuracy to ~1/10,000 or better, serving as the primary checkpoint in maintaining overall accuracy at approximately 99.99%. Distinguishing cognate from near-cognate substrates is critical, as exemplified by isoleucyl-tRNA synthetase (IleRS), which activates 200-fold more efficiently than the structurally similar through hydrophobic interactions in its that favor the larger β-branch of . Near-cognate amino acids like pose a challenge due to their similar chemical properties, but aaRSs employ kinetic discrimination and structural sieves to reject them, preventing incorporation errors that could alter protein function. These mechanisms are essential because aaRSs constitute a significant portion of the cellular , and defects in specificity amplify mistranslation rates, leading to proteotoxic stress from misfolded proteins and associated diseases such as neurodegeneration. The importance of this is underscored by the fact that mistranslation, even at low levels, triggers cellular responses and can exacerbate pathological conditions by increasing the burden of aberrant proteins on networks. In organisms from to humans, aaRS specificity ensures that the is faithfully decoded, with error correction further enhancing accuracy to 1 in 10^7 or better in many cases, thereby safeguarding integrity during protein synthesis. These mechanisms, combined with ribosomal , contribute to an overall error rate of approximately 1 in , safeguarding integrity.

Structural Classification

Class I and Class II Enzymes

Aminoacyl-tRNA synthetases (aaRS) are classified into two structurally distinct classes based on their catalytic domain architecture and the specific amino acids they recognize, reflecting independent evolutionary origins. Class I aaRS comprise 10 enzymes that primarily acylate tRNAs with amino acids such as arginine, cysteine, glutamine, glutamic acid, isoleucine, leucine, methionine, tryptophan, tyrosine, and valine. These enzymes typically handle a mix of small, polar, and larger hydrophobic residues, with examples including tyrosyl-tRNA synthetase (TyrRS), tryptophanyl-tRNA synthetase (TrpRS), and cysteinyl-tRNA synthetase (CysRS). In contrast, Class II aaRS also consist of 10 enzymes for alanine, asparagine, aspartic acid, glycine, histidine, lysine, phenylalanine, proline, serine, and threonine. These enzymes generally recognize small or hydrophobic amino acids, with representative members such as alanyl-tRNA synthetase (AlaRS), glycyl-tRNA synthetase (GlyRS), phenylalanyl-tRNA synthetase (PheRS), prolyl-tRNA synthetase (ProRS), seryl-tRNA synthetase (SerRS), and threonyl-tRNA synthetase (ThrRS). In some archaea and bacteria, a Class I paralog exists for lysine, but canonical eukaryotic LysRS is Class II. Notably, there is no overlap in the amino acid specificities between the two classes, ensuring complementary coverage of the genetic code. The catalytic domains of Class I aaRS are located at the and feature a Rossmann nucleotide-binding fold, characterized by a central parallel β-sheet flanked by α-helices. This fold accommodates ATP binding through two conserved signature motifs: HIGH (involved in recognition and phosphate coordination) and KMSKS (facilitating lysine-mediated stabilization of the during adenylate formation). An insert , often variable in length and positioned between the Rossmann motifs, contributes to tRNA recognition by interacting with the tRNA's acceptor stem and anticodon regions. These structural elements enable Class I enzymes to form the aminoacyl-adenylate intermediate on the α-phosphate side of ATP, positioning the activated for subsequent transfer to the 2'-OH of tRNA. Most Class I aaRS function as monomers or dimers, supporting efficient substrate binding in diverse cellular contexts. Class II aaRS, on the other hand, possess a catalytic domain typically situated toward the , built around a core of antiparallel β-sheets (usually six to seven strands) surrounded by α-helices. ATP coordination is mediated by three characteristic motifs (1, 2, and 3), which contain conserved residues like arginines that form "tweezers" to grip the backbone, stabilizing the in an orientation that allows aminoacyl-adenylate formation on the β-phosphate side. This class lacks the Rossmann fold and instead relies on the β-sheet scaffold for assembly, with tRNA binding occurring via the major groove of the acceptor . Quaternary structures vary, with most forming homodimers or homotetramers, while PheRS is uniquely heterotetrameric (α₂β₂), enhancing its specificity for the bulky side chain; ThrRS is homodimeric. The transfer of the aminoacyl group occurs to the 3'-OH of tRNA, distinguishing Class II from Class I mechanistically. In eukaryotes, such as humans, some aaRS exhibit additional complexity through appended domains that modulate function without altering core classification. For instance, TyrRS contains a WHEP domain, a RNA-binding motif inserted N-terminally, which influences tRNA affinity and may contribute to non-translational roles. These eukaryotic-specific appendages highlight adaptations in higher organisms while preserving the fundamental Class I and II distinctions in architecture and selectivity. Each is further subdivided into three subgroups (Ia–Ic and IIa–IIc), reflecting evolutionary divergences and functional specializations. Ia includes ValRS, LeuRS, and IleRS, which share similar Rossmann folds and often possess domains. Ib comprises GluRS, GlnRS, and (in some ) LysRS, with adaptations for polar substrates. Ic covers MetRS, ArgRS, CysRS, TyrRS, and TrpRS, featuring specialized anticodon recognition. For II, subgroup IIa (ProRS, AlaRS, GlyRS, ThrRS) emphasizes small aliphatic ; IIb (AsnRS, AspRS, LysRS, HisRS) handles charged/polar residues; and IIc (PheRS, SerRS) includes larger or specific hydrophobic/ hydroxylated . These subgroups correlate with tRNA modes and capabilities.
ClassAmino AcidsKey Structural FeaturesOligomerizationExamples
I, Cys, Gln, Glu, , Leu, Met, Trp, Tyr, ValN-terminal Rossmann ; HIGH and KMSKS motifs; insert domain for tRNAMostly monomeric/dimericTyrRS, TrpRS, CysRS
II, Asn, , Gly, His, Lys, Phe, , Ser, ThrC-terminal antiparallel β-sheet; motifs 1-3; tweezers for ATPDimeric/tetrameric (PheRS α₂β₂)AlaRS, GlyRS, PheRS, ProRS, SerRS, ThrRS

Domain Architecture

Aminoacyl-tRNA synthetases (aaRS) exhibit a modular domain architecture that enables precise recognition of , ATP, and tRNA substrates. The catalytic , responsible for and tRNA charging, differs markedly between the two structural classes. In Class I aaRS, this adopts a conserved Rossmann fold, characterized by a five-stranded parallel β-sheet flanked by α-helices, which serves as a nucleotide-binding to accommodate ATP and the in an cleft that also positions the tRNA 3'-end for transfer. In contrast, Class II aaRS feature a catalytic with a seven-stranded antiparallel β-sheet forming a barrel-like structure, incorporating three characteristic motifs (1-3) that facilitate ATP binding and create a cleft for the and tRNA acceptor end. These ensure specificity, with the cleft in both classes optimized for the geometry of the aminoacyl-adenylate intermediate. Accessory domains enhance substrate specificity and regulation. For tRNA recognition in Class I enzymes, the connective polypeptide 1 (CP1) domain, inserted into the Rossmann fold, contributes to anticodon binding and, in some cases like isoleucyl-tRNA synthetase, houses an editing subdomain for proofreading misacylated tRNAs. In Class II enzymes, an extension of motif 2 enables interactions with the tRNA major groove, aiding in acceptor stem and anticodon positioning. The amino acid-binding pocket varies by enzyme, relying on steric and electrostatic features; for example, in cysteinyl-tRNA synthetase (a Class I member), a coordinates the group of , enhancing discrimination against similar like serine or . Oligomerization states influence stability and function, with interfaces formed by catalytic or accessory . Many Class I aaRS, such as glutaminyl-tRNA synthetase, are monomeric, while most Class II enzymes are dimeric; however, phenylalanyl-tRNA synthetase forms an α₂β₂ heterotetramer, where β-subunits contribute additional tRNA-binding surfaces. Mitochondrial aaRS, such as human mitochondrial isoleucyl-tRNA synthetase (mtIleRS), often lack like CP1 to maintain compactness and frequently include N-terminal mitochondrial targeting sequences, contrasting with larger cytoplasmic isoforms that retain full modular complexity. Overall, aaRS range in size from approximately 300 to 1,000 , reflecting domain additions across . Structural studies have illuminated these architectures, beginning with the first Class I of glutaminyl-tRNA synthetase in 1989 at 2.8 Å , revealing the Rossmann fold and tRNA interactions. The inaugural Class II structure, of seryl-tRNA synthetase in 1990 at 2.5 Å, unveiled the β-barrel motif and major groove binding. Recent advances include cryo-EM structures of large complexes, such as phenylalanyl-tRNA synthetase, providing insights into heterotetrameric assembly and substrate coordination at near-atomic .

Enzymatic Mechanism

Amino Acid Activation

The amino acid activation step represents the initial phase of the aminoacylation reaction catalyzed by , in which the group of an performs a nucleophilic attack on the α-phosphate of ATP, forming a reactive aminoacyl-adenylate (AA-AMP) intermediate and releasing (). This ATP-dependent process is essential for priming the for subsequent transfer to tRNA and is facilitated by a two-metal ion mechanism involving two Mg²⁺ ions that coordinate and stabilize the triphosphate chain of ATP and the developing negative charges during bond formation. The overall reaction ensures high-energy coupling for the later ester bond formation while maintaining specificity in selection. The detailed chemical transformation can be expressed as: \text{R-CH(NH}_3^+)\text{-COO}^- + \text{ATP} \rightarrow \text{R-CH(NH}_3^+)\text{-CO-AMP} + \text{PP}_\text{i} where the aminoacyl moiety is covalently linked to the 5'- of AMP via a high-energy mixed anhydride bond. In class I aaRS enzymes, the HIGH motif within the Rossmann fold positions ATP in an extended conformation, enabling the carboxylate attack from the α-face of the ring; conversely, class II aaRS utilize motif 1 in their antiparallel β-sheet core to orient ATP in a bent configuration, promoting attack from the β-face. The subsequent release and cellular of PPi drive the reaction toward completion, rendering it effectively irreversible under physiological conditions. Specificity during arises from the precise architecture of the binding pocket, which discriminates based on side-chain ; for instance, valyl-tRNA synthetase (ValRS) features a hydrophobic pocket tailored to the isopropyl group of , sterically excluding bulkier analogs like . Kinetic analyses reveal typical Michaelis constants (Km) for cognate in the range of 10–100 μM and turnover numbers (kcat) of 1–10 s⁻¹, reflecting efficient adapted to cellular concentrations. The AA-AMP intermediate remains sequestered and protected within the enzyme's until tRNA , preventing unproductive ; its existence was first demonstrated through radiolabeling experiments using ³²P-ATP, which captured the enzyme-bound complex in early biochemical studies.

tRNA Charging and Transfer

The second step of aminoacylation, tRNA charging, transfers the activated from the aminoacyl-adenylate (AA-AMP) intermediate to the 3'-terminal CCA sequence of the cognate tRNA, catalyzed by aminoacyl-tRNA synthetases (aaRSs). The α-carboxylate group of the tRNA's terminal nucleophilically attacks the carbonyl carbon of the AA-AMP, displacing and forming a high-energy bond that links the amino acid to the tRNA. This is depicted as: \text{Aminoacyl-AMP} + \text{tRNA}^{\text{CCA}} \rightarrow \text{aminoacyl-tRNA}^{\text{CCA}} + \text{AMP} The process ensures covalent attachment of the correct amino acid to its tRNA for delivery to the ribosome during translation. To facilitate this transfer, aaRSs induce significant conformational changes in the tRNA, bending its structure into the canonical L-shape and positioning the acceptor stem's 3'-end precisely within the active site. Class I aaRSs approach and bind the minor groove of the tRNA acceptor stem-helix, while Class II aaRSs engage the major groove, enabling stereospecific alignment of the reacting groups despite the structural divergence between the two enzyme classes. These interactions stabilize the transition state and promote efficient nucleophilic attack.00074-1) The charging step proceeds rapidly compared to amino acid activation, with catalytic turnover rates (kcat) typically in the range of 10–100 s−1, which couples the half-reactions effectively and minimizes dissociation of the reactive AA-AMP intermediate. Upon completion of ester bond formation, the aminoacyl-tRNA product is generally released from the aaRS. However, in certain synthetases like alanyl-tRNA synthetase (AlaRS), the enzyme remains transiently bound to the charged tRNA, potentially allowing a brief assessment of charging fidelity prior to full dissociation. Experimental validation of the mechanism comes from stopped-flow kinetic analyses, which show that AMP release occurs synchronously with ester bond formation, indicating a concerted transfer without free diffusion of intermediates. Crystal structures of aaRS-tRNA complexes capturing post-transfer states, such as the Escherichia coli leucyl-tRNA synthetase-tRNALeu assembly from the early 2000s, illustrate the acceptor end's precise positioning and the enzyme's role in stabilizing the charged product.

Proofreading Mechanisms

Aminoacyl-tRNA synthetases (aaRSs) employ proofreading mechanisms to hydrolyze mischarged or misactivated products, ensuring in . The double-sieve model describes this process, where the synthetic acts as a coarse that activates and some similar noncognate ones, while a separate editing site functions as a fine to hydrolyze incorrect intermediates or products. Pre-transfer targets misactivated aminoacyl-adenylates (AA-AMP) in the synthetic site before transfer to tRNA, whereas post-transfer cleaves mis-aminoacylated tRNA in a dedicated hydrolytic site, often located 30–40 away. These mechanisms collectively reduce errors by 100- to 1,000-fold beyond initial specificity. In class I aaRSs, such as isoleucyl-tRNA synthetase (IleRS), valyl-tRNA synthetase (ValRS), and leucyl-tRNA synthetase (LeuRS), is mediated by the connective polypeptide 1 (CP1) domain, a ~150–200 residue insertion that forms the hydrolytic site. The CP1 domain hydrolyzes noncognate Val-AMP in pre-transfer editing or Thr-tRNA^Ile in post-transfer editing, often via water activation coordinated by conserved residues. For instance, ValRS , a similarly sized noncognate , by binding it in the pocket where a hydroxyl group triggers . Class II aaRSs utilize distinct editing architectures, typically an insertion between motifs 2 and 3 of the catalytic core. In threonyl-tRNA synthetase (ThrRS) and seryl-tRNA synthetase (SerRS), this hydrolyzes mischarged Ser-tRNA^Thr or other noncognate products through a tRNA-dependent conformational shift that positions the 3'-end for cleavage. Phenylalanyl-tRNA synthetase (PheRS), a heterotetrameric , employs a separate β-subunit containing the editing to perform post-transfer of Tyr-tRNA^Phe, preventing mistranslation of aromatic codons. The hydrolytic editing reaction mimics activity, with conserved aspartate and glutamate residues coordinating Mg^{2+} to activate a catalytic molecule for cleavage in mis-aminoacyl-tRNA. This substrate-assisted positions a non side chain to polarize the , excluding substrates via steric or electrostatic barriers. Some aaRSs, like methionyl-tRNA synthetase (MetRS), lack dedicated domains and rely solely on pre-sieve specificity for accuracy. Recent studies from the have revealed allosteric triggers in , where tRNA identity elements and conformational changes in the editing domain enhance discrimination, such as repositioning of residues to exclude substrates. In some archaeal aaRSs that lack intrinsic editing domains, dedicated trans-editing factors—standalone proteins homologous to editing domains—hydrolyze mischarged tRNAs to maintain .

Evolutionary History

Origins in Early Life

Aminoacyl-tRNA synthetases (aaRS) are believed to have originated prior to the (LUCA), with their emergence tied to the foundational steps of the and protein synthesis. Evidence from phylogenetic analyses indicates that aaRS enzymes reached a complex state before LUCA, potentially predating the full assembly of modern ribosomes, as their catalytic folds may have evolved from primordial -binding structures in prebiotic environments. The two major classes of aaRS—Class I and Class II— early in life's history, likely around 3.5 to 4 billion years ago, from distinct ancestral folds that reflect independent origins in recognition and . This pre-LUCA underscores the ancient role of aaRS in bridging and protein worlds. The co-evolution of aaRS specificity with the shaped the degeneracy observed in modern codon assignments, allowing for robust despite errors. In early life, the code likely incorporated fewer —estimates suggest 10 to 12 primitive ones, such as , , and —before expanding to the full 20 canonical set. aaRS enzymes provided the discriminatory power to assign these initial to codons, with less specific ancestral forms enabling a "statistical" system where multiple could be accommodated by overlapping specificities. Metagenomic reconstructions of ancestral sequences reveal conserved motifs in prokaryotic-like monomeric aaRS structures present in , supporting their role as foundational components of the translational apparatus across and . The transition from an to protein-dominated catalysis likely involved precursors for tRNA aminoacylation, which were gradually replaced by proteinaceous aaRS around 3.8 billion years ago. of demonstrates that molecules could catalyze attachment to tRNA-like structures, providing a plausible mechanism for prebiotic charging before the advent of encoded proteins. This shift coincided with the stabilization of the and the emergence of LUCA's translational machinery. Evidence from the geological record, including biogenic carbon isotopic signatures (δ¹³C values as low as -25‰) in 3.7 billion-year-old metasedimentary rocks from Greenland's Isua Supracrustal Belt, indicates early around that time.

Diversification and Gene Transfer

The diversification of aminoacyl-tRNA synthetases (aaRSs) across domains of life has been driven primarily by and (HGT), enabling adaptation to diverse cellular compartments and environmental pressures. Gene duplications have generated paralogous aaRS families, particularly in eukaryotes, where cytoplasmic and mitochondrial isoforms arose from the endosymbiotic integration of an α-proteobacterium approximately 1.5–2 billion years ago. This event led to the duplication of bacterial-origin aaRS genes in the nuclear genome, with subsequent targeting signals directing proteins to mitochondria. Phylogenetic analyses reveal that while many mitochondrial aaRS cluster with α-proteobacterial homologs, others show evidence of replacement or retargeting, reflecting ongoing evolutionary refinement post-endosymbiosis. Horizontal gene transfer has further expanded aaRS repertoires, especially in prokaryotes. In , HGT frequently involves aaRS genes linked to resistance, such as isoleucyl-tRNA synthetase (IleRS2) and methionyl-tRNA synthetase (MetRS2) variants transferred among Gram-positive pathogens like and via plasmids. These transfers confer resistance to inhibitors like , with phylogenetic evidence indicating ancient monophyletic origins followed by dissemination. In , class I aaRS, notably lysyl-tRNA synthetase (LysRS), were acquired from through HGT, as supported by functional and sequence data showing bacterial-like structures in archaeal genomes despite class II dominance in this domain. Organelle-specific evolution in eukaryotes highlights independent trajectories for mitochondrial aaRS, with humans encoding 19–20 dedicated nuclear genes for these enzymes to charge the 20 standard amino acids. However, losses have occurred, such as the absence of dedicated asparaginyl-tRNA synthetase (AsnRS), where asparaginyl-tRNA^Asn^ is instead formed via transamidation of aspartyl-tRNA^Asn^ by a separate amidotransferase. Similar indirect pathways exist for glutaminyl-tRNA^Gln^, underscoring reductive evolution in mitochondria. Phylogenomic studies in the 2020s have illuminated HGT patterns in extremophiles, revealing aaRS acquisitions that enhance stress tolerance, such as in thermophilic bacteria where duplicated genes support variant codon recognition. aaRS diversity varies markedly: bacteria maintain a minimal set of 19–20 genes for the canonical amino acids, while eukaryotes can expand to up to 48 genes, incorporating paralogs for organelles and specialized machinery like that for incorporation via phosphoseryl-tRNA synthetase. Codon table variations, such as the reassignment of UGA from stop to in species, are tied to aaRS adaptations, where tryptophanyl-tRNA synthetase gains specificity for a tRNA^Trp^ with a CUA anticodon, facilitating streamlining in these minimalistic . These evolutionary dynamics underscore aaRS as versatile components of machinery, shaped by duplication and transfer to meet organismal needs.

Non-Catalytic Aspects

Accessory Domains

Aminoacyl-tRNA synthetases (aaRSs) often feature domains that extend beyond the conserved catalytic cores, enabling , subcellular localization, and interactions with other cellular components. These non-catalytic appendages, which can constitute a significant portion of the enzyme's in higher organisms, facilitate oligomer stabilization and activity modulation without directly participating in aminoacylation. In eukaryotes, particularly humans, such domains have evolved to support multifaceted roles, including assembly into multi-synthetase complexes (MSCs) and responses to cellular stress. Prominent examples include the WHEP domain, a motif found in eukaryotic tyrosyl-tRNA synthetase (TyrRS) and histidyl-tRNA synthetase (HisRS), which promotes nuclear localization and protein-protein interactions essential for non-translational functions like and immune modulation. In TyrRS and HisRS, the WHEP domain mediates binding to nuclear factors such as and , facilitating activation under stress conditions. Similarly, the ELR motif, present in several human aaRSs including TyrRS and GluProRS, serves as a cytokine-like signal for and ; this tripeptide sequence (Glu-Leu-Arg) is exposed in fragmented forms like mini-TyrRS, enabling leukocyte and vascular endothelial growth factor receptor interactions. Regulatory domains further enhance aaRS functionality through interactions in MSCs. The tRNA synthetase-interacting multifunctional proteins (AIMPs), such as AIMP1 (p43/EMAPII) and AIMP2, act as scaffolds in the human , linking synthetases like GlnRS, ArgRS, and GluProRS to coordinate aminoacylation efficiency and ; for instance, AIMP1's EMAPII domain binds tRNA and supports stability. These domains collectively stabilize oligomeric states and harbor sites, such as those targeted by p38 , to fine-tune aaRS responsiveness. Structural studies have illuminated these appendages' architectures. X-ray crystallography and NMR of the EMAPII domain of AIMP1 associated with GlnRS reveal an oligonucleotide-binding (OB) fold that mimics evolutionary dimerization, supporting its role in tRNA binding and extracellular signaling; resolved in the early and refined in analyses, this structure highlights flexible linkers connecting it to the catalytic core. Overall, accessory domains underscore their evolutionary expansion for integrated cellular roles.

Functions Beyond Aminoacylation

Truncated forms of aminoacyl-tRNA synthetases (aaRSs), known as mini-synthetases, are secreted from cells and exhibit non-canonical functions in vascular biology. For instance, mini-tyrosyl-tRNA synthetase (mini-TyrRS), derived from the N-terminal catalytic domain of full-length TyrRS, is released extracellularly and promotes angiogenesis by binding to VE-cadherin on endothelial cells, thereby enhancing endothelial cell proliferation, migration, and tube formation. This interaction upregulates vascular endothelial growth factor receptor 2 (VEGFR-2) expression in a VE-cadherin-dependent manner, facilitating pro-angiogenic signaling without relying on its aminoacylation activity. Similarly, fragments of other aaRSs, such as mini-tryptophanyl-tRNA synthetase (mini-TrpRS), can antagonize these effects by competing for VE-cadherin binding sites, highlighting a regulatory balance in vascular homeostasis. Beyond vascular roles, secreted aaRS fragments contribute to immune modulation by acting as alarmins that trigger inflammatory responses. Human histidyl-tRNA synthetase (HisRS) splice variants are extracellularly released during cellular stress and function as pro-inflammatory cytokines, eliciting chemokine production and immune cell recruitment in conditions like inflammatory myositis. These fragments bind to innate immune receptors, amplifying inflammation through pathways involving chemokine receptors on T cells and immature dendritic cells. Additionally, processed forms of tyrosyl-tRNA synthetase (YRS) activate Toll-like receptor 2 (TLR2) on macrophages, enhancing tumor necrosis factor-alpha (TNF-α) secretion and monocyte chemotaxis, which sustains chronic inflammation independent of translation. Although specific TLR2 activation by methionyl-tRNA synthetase (MetRS) remains under investigation, related moonlighting functions of aaRSs underscore their broader role in innate immunity. In stress responses, aaRSs participate in adaptive signaling pathways decoupled from protein synthesis. Under hypoxic conditions, threonyl-tRNA synthetase (ThrRS), also known as TARS, is secreted and exerts anti-angiogenic effects by inhibiting VEGF-mediated endothelial responses, potentially through modulation of inflammatory cues like TNF-α. Phosphorylation events on related aaRSs, such as seryl-tRNA synthetase (SerRS), inactivate transcriptional repression under , linking aaRS activity to oxygen-sensing mechanisms. Furthermore, aaRSs integrate into amino acid sensing via the GCN2 pathway; amino acid deprivation elevates uncharged tRNAs, which bind and activate GCN2, triggering the integrated stress response to attenuate global while selectively enhancing stress-related . This GCN2-mediated sensing ensures to scarcity. The multi-synthetase complex () in eukaryotes assembles nine cytoplasmic aaRSs with three non-enzymatic accessory proteins (AIMPs), forming a macromolecular structure exceeding 1 MDa that coordinates beyond mere tRNA charging. This mega-complex regulates mRNA by associating with ribosomes and modulating formation, thereby fine-tuning protein synthesis efficiency under varying cellular demands. Components like glutamyl-prolyl-tRNA synthetase (EPRS) within the participate in the interferon-γ-activated inhibitor of (GAIT) complex, which binds 3' untranslated regions of inflammation-related mRNAs to suppress their post-infection or . Such regulatory roles extend MSC function to post-transcriptional control, influencing immune and metabolic . aaRSs also interact with viral pathogens, where host enzymes are co-opted for non-canonical purposes during infection. Human cytomegalovirus (HCMV) exploits the host machinery, including aaRSs, to sustain synthesis amid cellular stress, though specific hijacking mechanisms involve broader mRNA translation modulation rather than direct aaRS targeting. In cancer contexts, recent discoveries from the reveal aaRS involvement in regulation; for example, alanyl-tRNA synthetase (AARS1) senses in tumor microenvironments to drive lactylation, influencing autophagic flux and tumor progression independent of aminoacylation. These interactions highlight aaRSs' emergent roles in and oncogenic .

Clinical Relevance

Disease-Associated Mutations

Mutations in genes encoding aminoacyl-tRNA synthetases (aaRS) have been implicated in various human diseases, particularly those affecting the , , and oncogenesis. In Charcot-Marie-Tooth (CMT) disease, a hereditary , dominant missense mutations in GARS1 (encoding glycyl-tRNA synthetase, GlyRS) cause axonal forms such as CMT type 2D (CMT2D) and distal hereditary motor neuropathy type VA (dHMN-VA), characterized by progressive and primarily in the distal limbs. Over 40 pathogenic variants in GARS1 have been identified, many clustering in the catalytic domain and leading to impaired tRNA charging efficiency or disruption of multimeric synthetase complex (MSC) assembly, though the exact pathogenic mechanisms may involve toxic gain-of-function effects beyond aminoacylation deficits. Similarly, mutations in YARS1 (encoding tyrosyl-tRNA synthetase, TyrRS) underlie dominant intermediate CMT type C (DI-CMTC), with several reported variants, such as p.Glu196Lys, that compromise enzymatic activity and contribute to axonal degeneration through mechanisms potentially including altered non-canonical functions. In autoimmune disorders, autoantibodies targeting histidyl-tRNA synthetase (HisRS, encoded by HARS1) are central to antisynthetase syndrome (ASyS), a subset of idiopathic inflammatory myopathies. Anti-Jo-1 antibodies, specific to HisRS, are detected in approximately 20-30% of / cases and are strongly associated with , , , and Raynaud's phenomenon, with elevated levels correlating to disease severity and activity. These autoantibodies likely arise from molecular mimicry or exposure of cryptic epitopes on HisRS, triggering immune-mediated tissue damage, though the precise role of HisRS mutations remains less established compared to antibody-mediated effects. Neurodevelopmental disorders linked to aaRS mutations often involve white matter abnormalities due to disrupted protein synthesis in or neurons. Biallelic variants in AARS1 (encoding alanyl-tRNA synthetase, AlaRS) cause a recessive hypomyelinating with severe developmental delay, seizures, and , where loss-of-function mutations reduce aminoacylation and lead to global translation defects in affected brain regions. Likewise, mutations in DARS1 (encoding aspartyl-tRNA synthetase, AspRS) result in hypomyelination with and involvement and leg (HBSL), a progressive featuring , , and , with over 15 variants identified that impair tRNA charging and mitochondrial function. In cancer, tryptophanyl-tRNA synthetase (TrpRS, encoded by WARS1) exhibits dysregulated expression associated with tumor progression. Overexpression of WARS1 promotes in oral and other malignancies by enhancing cell invasiveness and , potentially through its angiostatic fragment T2-TrpRS acting paradoxically in a pro-tumorigenic context. mutations in WARS1 occur in approximately 4-6% of tumors across various types, including skin cutaneous and , often correlating with altered fidelity and immune evasion. Recent studies from 2023-2025 have highlighted mitochondrial aaRS in . Biallelic variants in RARS2 (mitochondrial arginyl-tRNA synthetase) cause progressive mitochondrial with features like , , and , as seen in expanded cohorts where novel compound heterozygous disrupt mitochondrial . Additionally, editing-deficient in both cytoplasmic and mitochondrial aaRS, such as those impairing deacylation of mischarged tRNAs, elevate mistranslation rates, contributing to proteotoxic stress and neurodegeneration in these disorders.

Pathophysiological Effects

Dysfunction in aminoacyl-tRNA synthetases (aaRS) can lead to substrate depletion, particularly in hyperproliferative states like cancer, where elevated aaRS activity accelerates aminoacylation and exhausts free pools. This depletion, especially of in glutamine-addicted tumors, activates the GCN2 kinase, which phosphorylates eIF2α and induces the , triggering an integrated response that promotes under nutrient . In such contexts, aaRS overactivity exacerbates metabolic vulnerabilities, as cancer cells exhibit 10- to 100-fold higher consumption compared to normal cells, linking aaRS-driven demands to broader disruptions. Impaired editing functions in aaRS, often due to , result in mistranslation, where non-cognate are incorporated into nascent polypeptides, causing proteome-wide errors and protein misfolding. These errors promote toxic in neurodegenerative disorders, as seen in the "sticky" model of AlaRS deficiency, where elevated serine misincorporation at alanine codons leads to selective neuronal loss and . Similarly, editing defects in ValRS generate global mistranslation effects, including altered protein function and aggregation-prone proteomes that contribute to neurodegeneration. In patients, such aaRS variants destabilize the enzymes, reducing tRNA charging fidelity and amplifying proteotoxic stress across cellular compartments. Secreted fragments of aaRS, derived from proteolytic cleavage, exert non-canonical effects on vascular biology, dysregulating in pathological settings like tumors and ischemia. For instance, the N-terminal mini-TyrRS fragment displays biphasic activity: low doses promote via cytokine-like signaling, while higher doses inhibit it, influencing and endothelial cell migration in ischemic tissues. Conversely, fragments of TrpRS, such as T2-TrpRS, act as angiostatic agents by disrupting endothelial cell junctions and suppressing pro- pathways like VEGF signaling in tumors. In cardiovascular diseases, aaRS deficiencies upregulate the unfolded protein response (UPR), enhancing VEGF expression and pathological during ischemia. aaRS contribute to immune dysregulation through autoantibody formation and extracellular signaling, as seen in where anti-aaRS antibodies, particularly against TrpRS, correlate with joint and arthropathies distinct from idiopathic RA. These autoantibodies target multiple cytoplasmic aaRS, potentially broadening the spectrum of anti-synthetase syndrome features in RA patients. In , viral infections like trigger aaRS autoantibodies via or alarmin release, with extracellular aaRS acting as potent proinflammatory mediators that amplify storms. This mechanism links aaRS to post-viral autoimmunity, as evidenced by elevated anti-OJ (IleRS) and anti-EJ (GlyRS) antibodies in cases following COVID-19. Quantitatively, pharmacological or genetic inhibition of aaRS substantially impairs global rates, with RNAi knockdown of glutamyl-tRNA synthetase reducing protein by up to 70% in model , underscoring their rate-limiting role in cellular . In human contexts, aaRS inhibitors suppress T-cell proliferation and production by mimicking amino acid starvation, decreasing efficiency in immune cells. Recent 2024 studies highlight aaRS involvement in inflammation, where anti-synthetase syndrome patients with aaRS autoantibodies face a 2- to 3-fold higher hospitalization risk during infection, driven by persistent proinflammatory aaRS release and UPR . As of 2025, ongoing clinical trials are exploring aaRS modulators for treating CMT and related neuropathies, showing promise in preclinical models for restoring fidelity.

Biotechnological and Computational Applications

Engineering for Synthetic Biology

Aminoacyl-tRNA synthetases (aaRS) have been engineered to incorporate non-canonical (ncAAs) into proteins, enabling expansion of the for applications. techniques, pioneered by the Schultz laboratory since the late 1990s, utilize positive and negative selection strategies to reassign codons, such as the stop codon (UAG), to ncAAs. These methods involve library-based of aaRS active sites followed by selection for efficient charging of orthogonal tRNAs with specific ncAAs while suppressing charging with canonical . For instance, variants of the tyrosyl-tRNA synthetase (TyrRS) have been evolved as suppressors, facilitating the site-specific incorporation of over 100 diverse ncAAs, including photocrosslinking and fluorescent probes, in , , and mammalian cells. Orthogonal aaRS/tRNA pairs, derived from archaea such as Methanocaldococcus jannaschii, minimize cross-reactivity with host translation machinery, ensuring specificity in ncAA incorporation. The M. jannaschii TyrRS/tRNATyrCUA pair, engineered through negative selection against endogenous synthetases (e.g., using toxic barnase expression) and positive selection for functional suppression (e.g., via β-lactamase), exhibits low recognition by eukaryotic synthetases and has been adapted for use in and mammalian systems. This orthogonality prevents mischarging and allows seamless integration into hosts without disrupting native protein synthesis. Engineered aaRS enable site-specific protein modifications for biotechnological purposes, such as labeling and enhancing therapeutic stability. For example, TyrRS variants incorporate alkyne-bearing ncAAs like propargyl-tyrosine, which undergo copper-catalyzed azide-alkyne (CuAAC) with -fluorophores for precise fluorescent tagging of proteins like GFP, achieving high labeling efficiency (>80%) while preserving function. In therapeutics, these systems support by incorporating - or alkyne-functionalized ncAAs into proteins such as human antagonists, yielding site-specific conjugates with 5–20 PEG chains that improve and bioactivity (e.g., IC50 values reduced by up to 10-fold compared to random ). Recent advances include multiplexed aaRS engineering for simultaneous incorporation of multiple ncAAs, expanding diversity. In 2021, strategies using quadruplet codon decoding with evolved tRNA/aaRS pairs enabled the site-specific insertion of up to four distinct ncAAs in a single protein, demonstrated in E. coli reporters with efficiencies approaching wild-type levels. In 2025, OrthoRep-mediated strategies enabled of aaRS in eight independent campaigns, yielding improved variants. Additionally, enhanced bioorthogonal noncanonical amino acid tagging (BONCAT) using engineered aaRS sets facilitates of newly synthesized proteins. Despite these progresses, engineering aaRS faces challenges in achieving and mitigating . Incorporation efficiencies must exceed 99% to avoid heterogeneous proteins, yet many variants show suppression yields below 50%, limited by tRNA competition and interference. Additionally, ncAA analogs can exhibit by off-target or metabolic interference, necessitating refined selection schemes to enhance specificity and cellular tolerance.

Prediction and Modeling Tools

Computational tools for predicting the structures of aminoacyl-tRNA synthetases (aaRS) have revolutionized the field by providing high-fidelity models where experimental data is limited. The system, released in 2021, has generated predicted three-dimensional structures for all 20 human cytoplasmic and mitochondrial aaRS, accessible via the . These models demonstrate exceptional accuracy, with predicted local distance difference test (pLDDT) scores surpassing 90 for the catalytic domains in the majority of cases, enabling reliable insights into geometries and substrate binding. In 2024, advanced this further by incorporating diffusion-based architectures for joint structure prediction of protein complexes, including aaRS-tRNA pairs, achieving median backbone RMSDs under 2 Å for many biomolecular interactions and addressing previous gaps in modeling dynamic assemblies. Servers dedicated to modeling aaRS interactions with tRNA and substrates focus on specificity determinants and recognition mechanisms. tRNAmodpred, a computational tool launched in 2016, predicts post-transcriptional modifications in tRNA sequences, which critically influence aaRS recognition sites by stabilizing anticodon loops and acceptor stems for accurate aminoacylation. For aaRS-specific specificity modeling, machine learning approaches like those applied to pyrrolysyl-tRNA synthetase (PylRS) use random forest classifiers trained on structural and sequence features to forecast substrate acceptance, achieving up to 85% accuracy in distinguishing cognate from non-cognate amino acids. These tools integrate evolutionary alignments and energy-based docking to simulate binding affinities, aiding in the design of orthogonal aaRS variants. Key databases support aaRS prediction by curating structural, functional, and data. Rfam catalogs families, including tRNA motifs essential for aaRS interaction, with models enabling prediction of tRNA secondary structures across genomes. provides domain annotations for aaRS, identifying class I and II catalytic cores alongside accessory motifs, facilitating automated classification based on hidden Markov models with sensitivities exceeding 95% for known families. As of 2025, has expanded its variant effect predictions through integration of models and pathogenicity scores from tools like AlphaMissense. Function prediction tools leverage to infer aaRS activities from sequences. Sequence-based classifiers, such as those using domain profiles, assign aaRS to classes I or II with accuracies above 90%, by detecting Rossmann folds or antiparallel β-sheets characteristic of ATP-binding sites. For incorporation efficiency, models using on PylRS variants predict activity of evolved mutants, achieving up to 11-fold improvements in ncAA suppression efficiency. These approaches prioritize seminal features from high-impact studies, such as evolutionary conserved residues, to forecast aminoacylation rates without exhaustive wet-lab validation. Despite advances, prediction tools face limitations in handling (HGT) variants, which introduce chimeric aaRS architectures across prokaryotic lineages, complicating phylogenetic classifiers and reducing model confidence for non-canonical isoforms. A 2025 development integrates protein models with automated biofoundry platforms to evolve aaRS variants, improving ncAA incorporation , as shown for specific ncAAs like p-acetylphenylalanine with up to 2.4-fold activity gains.

References

  1. [1]
    Aminoacyl-tRNA synthetases - PMC - PubMed Central
    The aminoacyl-tRNA synthetases are an essential and universally distributed family of enzymes that plays a critical role in protein synthesis.
  2. [2]
    Aminoacyl-tRNA synthetases: Structure, function, and drug discovery
    Aminoacyl-tRNA synthetases (AARSs) are the enzymes that catalyze the aminoacylation reaction by covalently linking an amino acid to its cognate tRNA.
  3. [3]
    Aminoacyl-tRNA synthetases in human health and disease - PMC
    Oct 18, 2022 · This review provides an overview of the basic biology of aaRS proteins and describes the rapidly growing list of human diseases known to be caused by genetic ...
  4. [4]
  5. [5]
    Biochemistry of Aminoacyl tRNA Synthetase and tRNAs ... - Frontiers
    Aminoacyl tRNA synthetases (AARSs) were first identified as activating enzymes in 1958, responsible for activating amino acids in the presence of ATP. Only ...
  6. [6]
    The complex evolutionary history of aminoacyl-tRNA synthetases
    Aminoacyl-tRNA synthetases (AARSs) are very ancient house-keeping enzymes that are present in all eukaryotes, archaea and bacteria. They mediate the accurate ...Missing: universality | Show results with:universality
  7. [7]
  8. [8]
  9. [9]
    NMR analyses of the conformations of L-isoleucine and L-valine ...
    Such hydrophobic interaction with IleRS is more significant for L-isoleucine than for L-valine. The TRNOE analysis is useful for studying the amino acid ...
  10. [10]
  11. [11]
    The amino acid substitution affects cellular response to mistranslation
    We hypothesize that mistranslating tRNAs are genetic modifiers of disease by increasing the level of proteotoxic stress. This increased stress could lead to the ...
  12. [12]
    Low level genome mistranslations deregulate the transcriptome and ...
    Jun 20, 2012 · Aggregation of mistranslated proteins exacerbates proteotoxic stress, increases ATP consumption and activates the general stress response (ESR) ...
  13. [13]
  14. [14]
    On the Evolution of Structure in Aminoacyl-tRNA Synthetases - PMC
    The aminoacyl-tRNA synthetases are one of the major protein components in the translation machinery. These essential proteins are found in all forms of life and ...
  15. [15]
    Coding of Class I and II aminoacyl-tRNA synthetases - PMC
    In contrast, Class II aaRS active sites are formed from antiparallel β-strands. These structural differences [10] motivated substantial effort to understand why ...
  16. [16]
    Domain acquisition by class I aminoacyl-tRNA synthetase urzymes ...
    All Class I aaRS share the same three domains (Figure 1): a Rossmann dinucleotide-binding catalytic domain, variable-length insertions between the two crossover ...
  17. [17]
    Structural and functional relationships between aminoacyl-tRNA ...
    The core of class I synthetases is the classical nucleotide-binding domain with its characteristic Rossmann fold. In contrast, the active site of class II ...
  18. [18]
    Class II Aminoacyl Transfer Rna Synthetases: Crystal Structure of ...
    These three sequence motifs are contained in the catalytic site domain, built around an antiparallel β sheet, and flanked by three α helices that form the ...
  19. [19]
    A recurrent RNA-binding domain is appended to eukaryotic ...
    This repeated motif may represent a novel type of general RNA-binding domain appended to eukaryotic aminoacyl-tRNA synthetases to serve as a cis-acting tRNA- ...Missing: WHEP TyrES
  20. [20]
    Structure of E. coli Glutaminyl-tRNA Synthetase Complexed with ...
    The crystal structure of Escherichia coli glutaminyl-tRNA synthetase (GlnRS) complexed with its cognate glutaminyl transfer RNA (tRNA Gln ) and adenosine ...
  21. [21]
    A second class of synthetase structure revealed by X-ray analysis of ...
    Sep 20, 1990 · The three-dimensional crystal structure of seryl-transfer RNA synthetase from Escherichia coli, refined at 2.5 Å resolution, is described.
  22. [22]
    Adaptation to tRNA acceptor stem structure by flexible adjustment in ...
    Class I aminoacyl-tRNA synthetases (aaRSs) use a Rossmann-fold domain to catalyze the synthesis of aminoacyl-tRNAs required for decoding genetic information.
  23. [23]
    Aminoacyl-tRNA Synthetases in the Bacterial World | EcoSal Plus
    Class I aaRSs are mostly monomers, and class II aaRSs are mostly dimers (Table 1). It is noteworthy that class I TrpRS (63) and TyrRS (64) are dimers and ...
  24. [24]
    Zinc-mediated amino acid discrimination in cysteinyl-tRNA synthetase
    These results argue strongly for a major role for the zinc ion in amino acid discrimination by CysRS, where the tight zinc-thiolate interaction and the strict ...Missing: pocket CysTS
  25. [25]
    tRNA synthetase: tRNA Aminoacylation and beyond - PMC
    The aminoacyl-tRNA synthetases (aaRSs) comprise an ancient family of enzymes that are responsible for the first step of protein synthesis.
  26. [26]
    Mitochondrial Aminoacyl-tRNA Synthetases - NCBI - NIH
    Aminoacyl-tRNA synthetases (aaRSs) are nuclear encoded, synthesized in the cytosol and imported. Thus, two to three sets of aaRSs coexist in eukaryotic cells.Introduction · Structural and Functional... · Gene Relationships Between...
  27. [27]
    Crystal structure of human mitochondrial PheRS complexed with ...
    Jan 20, 2012 · Here, we describe the first crystal structure of mitochondrial aminoacyl-tRNA synthetase (aaRS) complexed with tRNA at a resolution of 3.0 Å.Missing: cryo- EM
  28. [28]
    Methods for kinetic and thermodynamic analysis of aminoacyl-tRNA ...
    The most common pre-steady state kinetic approaches for the aaRSs are rapid chemical quench assays, which follow rates of product formation, and stopped-flow ...
  29. [29]
    The 2 Å crystal structure of leucyl-tRNA synthetase and its complex ...
    We describe the first crystal structure of a leucyl-tRNA synthetase, from the hyperthermophile Thermus thermophilus, at 2.0 Å resolution.<|control11|><|separator|>
  30. [30]
  31. [31]
    Kinetic Partitioning between Synthetic and Editing Pathways in ... - NIH
    ... increased 100-fold (Table 1). This results in a low discrimination factor (116) and implicates the need for hydrolytic editing to prevent mistranslation (42).
  32. [32]
    CP1-dependent partitioning of pretransfer and posttransfer editing in ...
    For class I tRNA synthetases, the editing activity is encoded by the CP1 domain, which is distinct from the active site for aminoacylation. What is not clear is ...
  33. [33]
    Mechanistic insights into cognate substrate discrimination ... - PNAS
    Nov 22, 2010 · Editing/proofreading by aminoacyl-tRNA synthetases is an important quality control step in the accurate translation of the genetic code that removes noncognate ...
  34. [34]
    Hydrolytic editing by a class II aminoacyl-tRNA synthetase | PNAS
    E. coli proline-tRNA synthetase (ProRS) contains a large insertion domain of unknown function within its amino acid activation site (20). We hypothesized that ...
  35. [35]
    The role of tRNA identity elements in aminoacyl-tRNA editing - PMC
    Jul 18, 2024 · Here, we discuss how the same identity elements that define tRNA aminoacylation play an integral role in aminoacyl-tRNA editing.
  36. [36]
    Trans-editing of mischarged tRNAs - PNAS
    Here, we report specific tRNA-dependent trans-editing by aaRS-like proteins that reciprocate the editing domains of aaRSs, but not the remainder of the ...
  37. [37]
    The evolution of aminoacyl-tRNA synthetases: From dawn to LUCA
    Sep 8, 2020 · The origin of all extant life on earth is intimately linked to the establishment of the principal components of the Genetic Code.Missing: early | Show results with:early
  38. [38]
  39. [39]
    Emergence and Evolution - PMC - PubMed Central
    The aaRSs are an ancient enzyme family believed to have origins that may predate the last common ancestor and as such they provide insights into the evolution ...
  40. [40]
    Molecular Evolution of Aminoacyl tRNA Synthetase Proteins in the ...
    Aminoacyl-tRNA synthetases (aaRS) consist of several families of functionally conserved proteins essential for translation and protein synthesis.
  41. [41]
    The evolutionary history of class I aminoacyl-tRNA synthetases indicates early statistical translation
    **Summary of Evolutionary History of Class I Aminoacyl-tRNA Synthetases:**
  42. [42]
    An in vitro evolved precursor tRNA with aminoacylation activity - PMC
    According to the RNA world hypothesis, however, the early translation system should have used ARS-like ribozymes for the aminoacylation of tRNAs or tRNA-like ...
  43. [43]
    Origin and Evolution of the Mitochondrial Aminoacyl-tRNA ...
    Endosymbiotic models for the origin of mitochondria posit that there was a massive transfer of genes from the bacterial endosymbiont to the nuclear genome of ...
  44. [44]
  45. [45]
    Aminoacyl‐tRNA synthesis in archaea: different but not unique
    Apr 9, 2003 · The only exception, suggested from both functional and phylogenetic data, appears to be the horizontal transfer of a class I LysRS from a ...
  46. [46]
    Biogenesis of glutaminyl-mt tRNAGln in human mitochondria - PMC
    We demonstrate here that human mt glutamyl-tRNA synthetase (mtGluRS) efficiently misaminoacylates mt tRNA Gln to form Glu-tRNA Gln.Results · Fig. 2 · Cytoplasmic Trna Is A...
  47. [47]
    Diversification of aminoacyl-tRNA synthetase activities via genomic ...
    Aug 18, 2022 · In addition to facilitating the synthesis of antibiotics, acquisition of supplementary aaRS genes to gain antibiotic resistance has been ...
  48. [48]
    The complex evolutionary history of aminoacyl-tRNA synthetases
    Nov 28, 2016 · Aminoacyl-tRNA synthetases (AARSs) are very ancient house-keeping enzymes that are present in all eukaryotes, archaea and bacteria. They mediate ...
  49. [49]
    Characterization of Aminoacyl-tRNA Synthetases in Chromerids
    ... AaRS genes: 48 genes encoding AaRSs were identified in C. velia, while only 39 AaRS genes were found in V. brassicaformis. In the latter alga, ArgRS and ...
  50. [50]
    UGA is read as tryptophan in Mycoplasma capricolum - PubMed
    We show that UGA also codes for tryptophan in Mycoplasma capricolum, a wall-less bacterium having a genome only 20-25% the size of the Escherichia coli genome.Missing: table aaRS changes
  51. [51]
    Aminoacyl-tRNA synthetases and amino acid signaling
    The aminoacylation of tRNAs by ARSs is a high-fidelity process usually composed of two steps. ARS activates their cognate amino acid using ATP, producing an ...
  52. [52]
    Crystal structure of a human aminoacyl-tRNA synthetase cytokine
    The CP1 domain is circled. The critical ELR motif (orange) for cytokine activity is located on α5 of the catalytic domain and is close to α14 of the anticodon- ...Abstract · Sign Up For Pnas Alerts · Results
  53. [53]
    Aminoacyl‐tRNA synthetases: a family of expanding ... - EMBO Press
    An elegant series of experiments clearly show that mature tRNAs are charged in the nucleus prior to export to the cytoplasm (Lund and Dahlberg, 1998). Blockage ...Introduction · Aarss Perform Dual And... · Specific Aars--Trna...<|control11|><|separator|>
  54. [54]
    Roles of aminoacyl-tRNA synthetase-interacting multi-functional ...
    Jul 24, 2020 · In this review, we summarize the biological functions of AIMP1, EMAP II, AIMP2, AIMP2-DX2, and AIMP3. Also, we systematically introduce their emerging roles in ...
  55. [55]
    Structure of the ArgRS–GlnRS–AIMP1 complex and its ... - PNAS
    We report a crystal structure of the MSC subcomplex comprising ArgRS, glutaminyl-tRNA synthetase (GlnRS), and the auxiliary factor aminoacyl tRNA synthetase ...
  56. [56]
  57. [57]
    Structure of the EMAPII domain of human aminoacyl-tRNA ... - NIH
    The EMAPII (endothelial monocyte-activating polypeptide II) domain is a tRNA-binding domain associated with several aminoacyl-tRNA synthetases, which becomes an ...Missing: ray | Show results with:ray
  58. [58]
    Structure of the EMAPII domain of human aminoacyl‐tRNA ...
    The EMAPII (endothelial monocyte‐activating polypeptide II) domain is a tRNA‐binding domain associated with several aminoacyl‐tRNA synthetases, ...Missing: ray GlnRS
  59. [59]
    The novel fragment of tyrosyl tRNA synthetase, mini‐ TyrRS, is ...
    Dec 28, 2007 · Mini-TyrRS binding to ECs. Because mini-TyrRS has angiogenic activity in vivo, we hypothesized that the secreted mini-TyrRS may act on ECs.
  60. [60]
    Inhibition of mini-TyrRS-induced angiogenesis response in ...
    Mini-TyrRS was able to increase the protein expression of VEGFR-2 in the presence of VE-cadherin, while no stimulatory effect of mini-TyrRS was detected when VE ...
  61. [61]
    Identification of a residue crucial for the angiostatic activity of human ...
    Apr 20, 2016 · We conclude that the Lys153 residue of human mini TrpRS is a VE-cadherin binding site and is therefore crucial for its angiostatic activity.Missing: pro- | Show results with:pro-
  62. [62]
    Secreted Histidyl-tRNA Synthetase Splice Variants Elaborate Major ...
    Background: Autoantibodies (anti-Jo-1) to cytoplasmic histidyl-tRNA synthetase (HisRS) are associated with inflammatory myositis.Missing: alarmin | Show results with:alarmin
  63. [63]
    Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase ...
    Sep 16, 2002 · Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature ...
  64. [64]
    Roles of aminoacyl-tRNA synthetases in immune regulation and ...
    Nov 28, 2019 · Aminoacyl-tRNA synthetases (ARSs) play a vital role in protein synthesis by linking amino acids to their cognate transfer RNAs (tRNAs).Arss In Immune Cell... · Arss In Immune Diseases · Arss And Autoimmune Diseases
  65. [65]
    Matrix metalloproteinases inactivate the proinflammatory functions of ...
    The moonlighting functions of the aminoacyl-tRNA synthetases are primarily mediated by additional domains in higher eukaryotic tRNA synthetases (6, 19).
  66. [66]
    Secreted Threonyl-tRNA synthetase stimulates endothelial cell ...
    Feb 21, 2013 · Here we report that TARS is secreted in response to inflammatory or angiogenic signaling, and that the anti-angiogenic effect of TARS inhibition ...
  67. [67]
    Phosphorylation of seryl-tRNA synthetase by ATM/ATR is essential ...
    Dec 22, 2020 · Here, we reveal that the transcriptional repressor role of SerRS is inactivated under hypoxia through phosphorylation by ataxia telangiectasia ...Missing: threonyl- | Show results with:threonyl-
  68. [68]
    Aminoacyl-tRNA synthetase inhibition activates a pathway ... - PubMed
    Apr 21, 2020 · We propose that GCN1 participates in a previously unrecognized amino acid sensor pathway that branches from the canonical AAR. Keywords: GCN1; ...
  69. [69]
    Uncharged tRNA Activates GCN2 by Displacing the Protein Kinase ...
    It is thought that GCN2 is activated by uncharged tRNAs that accumulate in amino acid–starved cells partly because mutations in aminoacyl tRNA synthetases ( ...<|separator|>
  70. [70]
    3-Dimensional architecture of the human multi-tRNA synthetase ...
    The essential function of the aminoacyl tRNA synthetases (AARSs) is mRNA decoding during protein synthesis. They catalyze ATP-dependent charging of tRNA with ...
  71. [71]
    Phosphocode-dependent glutamyl-prolyl-tRNA synthetase 1 ...
    Oct 2, 2023 · The GAIT complex inhibits the translation of specific mRNAs that bear RNA hairpins, known as GAIT elements, in their 3' untranslated regions (3' ...Missing: aaRS | Show results with:aaRS
  72. [72]
    Human Cytomegalovirus Strategies to Maintain and Promote mRNA ...
    Here we review key regulatory steps in mRNA translation, and the strategies used by HCMV to maintain protein synthesis in infected cells.Missing: synthetase | Show results with:synthetase
  73. [73]
    Alanyl-tRNA synthetase, AARS1, is a lactate sensor and ... - Cell Press
    Apr 22, 2024 · AARS1 functions as a lactate sensor that mediates global lysine lacylation in tumor cells. AARS1 binds to lactate and catalyzes the formation of lactate-AMP.Missing: autophagy | Show results with:autophagy
  74. [74]
    Roles of Aminoacyl-tRNA Synthetases in Cancer - Frontiers
    Nov 26, 2020 · Here, we introduce the roles of ARSs and AIMPs in certain cancers, such as colon cancer, lung cancer, breast cancer, gastric cancer and pancreatic cancer.Missing: autophagy | Show results with:autophagy
  75. [75]
    GARS1-Associated Axonal Neuropathy - GeneReviews - NCBI - NIH
    Nov 8, 2006 · GARS1 adolescent- or early adult-onset hereditary motor/sensory neuropathy (encompassing the phenotypes also referred to as Charcot-Marie-Tooth ...Diagnosis · Clinical Characteristics · Management · Genetic Counseling
  76. [76]
    The recurrent missense mutation p.(Arg367Trp) in YARS1 causes a ...
    Sep 18, 2021 · Mutations in YARS1 have been associated with autosomal-dominant Charcot-Marie-Tooth (CMT) neuropathy type C and a heterogenous group of ...
  77. [77]
    The Diagnosis and Treatment of Antisynthetase Syndrome - NIH
    Anti-synthetase syndrome is an autoimmune disease characterized by autoantibodies against one of many aminoacyl transfer RNA (tRNA) synthetases with clinical ...
  78. [78]
    Article Expanded phenotype of AARS1-related white matter disease
    We suggest that variants in AARS1 result in a broader clinical spectrum than previously appreciated. The predominant form results in early infantile–onset ...Missing: neurodevelopmental | Show results with:neurodevelopmental
  79. [79]
    Leukoencephalopathy hypomyelination with brainstem and spinal ...
    HBSL is caused by missense mutations in the DARS1 gene encoding the aspartyl-tRNA synthetase, conferring non-synonymous amino acid substitutions in highly ...Abstract · Introduction · Clinical symptoms and... · Discussion
  80. [80]
    Overexpressed tryptophanyl-tRNA synthetase, an angiostatic protein ...
    Sep 8, 2015 · Importantly, the TrpRS levels were significantly higher in tumor cells from metastatic lymph nodes than in corresponding primary tumor cells.Results · Trprs Knockdown Reduces Cell... · Trprs Overexpression...Missing: WARS1 | Show results with:WARS1
  81. [81]
    Multi-Omics Database Analysis of Aminoacyl-tRNA Synthetases in ...
    Here, we analyze publicly available genomic and transcriptomic data on human cytoplasmic and mitochondrial aaRSs across many cancer types.3. Results · 3.1. Genomic Variations... · 3.3. Gene Expression (mrna)Missing: autophagy | Show results with:autophagy
  82. [82]
    Expanded clinical phenotype and untargeted metabolomics analysis ...
    Mar 4, 2024 · RARS2-related mitochondrial disorder is an autosomal recessive mitochondrial encephalopathy caused by biallelic pathogenic variants in the gene ...
  83. [83]
    Mitochondrial aminoacyl-tRNA synthetases trigger unique ...
    Nov 17, 2023 · This study investigates the molecular mechanisms triggered by three different mt-ARS defects caused by biallelic mutations in AARS2, EARS2, and RARS2.
  84. [84]
    Novel insights into the GCN2 pathway and its targeting ... - FEBS Press
    Jun 16, 2024 · ... GCN2 may be due to the metabolic subgroup of cancer cells. For instance, in glutamine-addicted tumor cells, amino acid deprivation leads to GCN2 ...
  85. [85]
    The GCN2‐ATF4 pathway is critical for tumour cell survival and ...
    In this study, we report that ATF4 is necessary for tumour cells to maintain homeostasis of amino acid metabolism and that activation of GCN2‐ATF4‐asparagine ...Missing: aminoacyl overactivity addiction
  86. [86]
    Rethinking glutamine metabolism and the regulation of ... - Frontiers
    Specifically, cancer cells consume 10–100-fold more glutamine than they do any other amino acids. Glutamine is the most abundant non-essential amino acid in the ...Missing: aminoacyl tRNA overactivity GCN2
  87. [87]
    Errors in Translation Cause Selective Neurodegeneration
    The finding that the sti mutation targets the editing domain of AlaRS is highly significant because it suggests that amino acid substitutions will be introduced ...Missing: mistranslation | Show results with:mistranslation
  88. [88]
    Global Effects of Mistranslation from an Editing Defect in Mammalian ...
    Because the mutant ValRS studied here acquired the ability to cause amino acid misincorporation, the mutation can be viewed as a gain-of-function mutation. As ...
  89. [89]
    Deficiencies in tRNA synthetase editing activity cause ... - PNAS
    Nov 24, 2014 · In mice, a point mutation (A734E) in the AlaRS editing domain in the mutant strain “sticky” caused a twofold increase in Ser-mischarged tRNAAla ...
  90. [90]
    Effect of mini-tyrosyl-tRNA synthetase on ischemic angiogenesis ...
    These data show that mini-TyrRS has dose-dependent biphasic effects on ischemic angiogenesis and vascular permeability in vivo, that is, antiangiogenic and ...
  91. [91]
    Inhibition of tumor angiogenesis by a natural fragment of a tRNA ...
    Fragments of TyrRS stimulate angiogenesis, whereas those of TrpRS (T2-TrpRS) inhibit angiogenesis. Thus, these two synthetases acquired opposing activities ...Research Focus · Introduction · Ve-Cadherin As A Target For...Missing: ischemia | Show results with:ischemia
  92. [92]
    Aminoacyl-Transfer RNA Synthetase Deficiency Promotes ...
    Jan 28, 2016 · Together, these results suggest that defects in either tars or iars result in increased angiogenesis via upregulation of the UPR pathway. AARSs ...Results · Upr Pathway And Vegfaa Are... · Upr Pathway Signaling Is...
  93. [93]
    Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and ...
    May 13, 2022 · Autoantibodies against TrpRS have been found in patients with autoimmune diseases, where the clinical features were associated with rheumatoid ...
  94. [94]
    Autoantigenic properties of the aminoacyl tRNA synthetase family in ...
    Dec 2, 2022 · Our results suggest that most, if not all, cytoplasmic aaRS may become autoantigenic. Autoantibodies against new aaRS may be found in plasma ...
  95. [95]
    Aminoacyl-tRNA synthetases function as alarmins in RA - Nature
    Aug 3, 2023 · Findings from a new study reveal that extracellular ARSs function as potent alarmins in RA and could be a therapeutic target.Missing: autoantibodies | Show results with:autoantibodies
  96. [96]
    Anti-OJ antibody-positive anti-synthetase syndrome following SARS ...
    Aug 29, 2024 · COVID-19 can induce a systemic inflammatory response with variable clinical manifestations. Similar to various viruses, COVID-19 has been ...
  97. [97]
    Cytoplasmic and mitochondrial aminoacyl-tRNA synthetases ...
    Nov 18, 2022 · We show that RNAi knockdown of the cytoplasmic glutamyl-tRNA synthetase gene ears-1 greatly shortens lifespan and substantially inhibits the translation rate.
  98. [98]
  99. [99]
    Anti-synthetase syndrome is associated with a higher risk ... - Frontiers
    Mar 3, 2024 · Anti-synthetase syndrome is associated with a higher risk of hospitalization among patients with idiopathic inflammatory myopathy and COVID-19.
  100. [100]
    At the Interface of Chemical and Biological Synthesis: An Expanded ...
    The ability to site-specifically incorporate noncanonical amino acids (ncAAs) with novel structures into proteins in living cells affords a powerful tool to ...Missing: seminal papers
  101. [101]
  102. [102]
    A general approach for the generation of orthogonal tRNAs
    The mutant suppressor tRNA Tyr CUA together with the M. jannaschii TyrRS is an excellent orthogonal tRNA–synthetase pair for the in vivo incorporation of ...
  103. [103]
    Role of tRNA Orthogonality in an Expanded Genetic Code - PMC
    The generation of such orthogonal tRNA/aaRS pairs is typically based on the distinct identity elements used by bacterial, archaeal, and eukaryotic tRNAs. For ...
  104. [104]
    Genetic Code Expansion Enables Site-Specific PEGylation of ... - NIH
    As an alternative to nonspecific PEGylation, we report the use of genetic code expansion technology to site-specifically incorporate the unnatural amino acid ...Missing: aaRS | Show results with:aaRS
  105. [105]
  106. [106]
    Multiplex suppression of four quadruplet codons via tRNA directed ...
    Sep 29, 2021 · We showcase the multiplexed decoding of up to four unique quadruplet codons by their corresponding qtRNAs in a single reporter.<|separator|>
  107. [107]
    Improving the Efficiency and Orthogonality of Genetic Code Expansion
    However, cellular biosynthesis of ncAA-containing proteins with high efficiency and fidelity is a formidable challenge. In this review, we summarize up-to ...
  108. [108]
    Genetic Code Expansion: Recent Developments and Emerging ...
    Dec 31, 2024 · In this review, we cover the principles of GCE, including the optimization of the aminoacyl-tRNA synthetase (aaRS)/tRNA system and the ...
  109. [109]
    AlphaFold Protein Structure Database
    AlphaFold is an AI system developed by Google DeepMind that predicts a protein's 3D structure from its amino acid sequence. It regularly achieves accuracy ...AlphaFold · Downloads · View protein · FAQsMissing: tRNA synthetases<|control11|><|separator|>
  110. [110]
    Accurate structure prediction of biomolecular interactions ... - Nature
    May 8, 2024 · Here we describe our AlphaFold 3 model with a substantially updated diffusion-based architecture that is capable of predicting the joint structure of complexes.
  111. [111]
    tRNAmodpred: A Computational Method for Predicting ... - PubMed
    Sep 1, 2016 · This method allows for predicting modification patterns for newly sequenced genomes as well as for checking tentative modification status of tRNAs.Missing: tool aminoacyl synthetase
  112. [112]
    Machine Learning Enables Prediction of Pyrrolysyl-tRNA Synthetase ...
    Aug 18, 2023 · Machine learning models were developed to predict the substrate specificity of PylRS to accept novel NCAAs that could be incorporated into proteins by three ...
  113. [113]
    Prediction and classification of aminoacyl tRNA synthetases using ...
    Sep 22, 2010 · Aminoacyl tRNA synthetases (aaRSs) play a central role in protein translation by covalently linking the correct amino acid to its cognate ...Sequence Similarity Search · Methods · Prosite And Interproscan
  114. [114]
    Machine learning-guided evolution of pyrrolysyl-tRNA synthetase for ...
    Jul 19, 2025 · Selecting aminoacyl-tRNA synthetase/tRNA pairs for efficient genetic encoding of noncanonical amino acids into proteins ... AlphaFold3, was ...<|control11|><|separator|>
  115. [115]
    Horizontal gene transfer in aminoacyl-tRNA synthetases ... - PubMed
    Phylogenetic profiles are in agreement with previous observations that many genes for aminoacyl-tRNA synthetases were transferred horizontally between species ...
  116. [116]
    Integrating protein language models and automatic biofoundry for ...
    Feb 11, 2025 · This study devises a protein language model-enabled automatic evolution platform, a closed-loop system for automated protein engineering within ...